Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ORMP

Oramed Pharmaceuticals, Inc

Dec 13 • 04:00PM ET

2.47

Dollar change -0.02
Percentage change -0.80	%

Healthcare • Biotechnology • USA • NASD

Peers: MNKD VTVT LGND TNDM XERS NVAX AQST CAPR RIGL

| Held by: IWC SPDW DFAC AVSC GWX DFAT DFAS DCOR AVUS DFUS

Scroll to Statements

Index	-	P/E	22.66	EPS (ttm)	0.11	Insider Own	15.57%	Shs Outstand	40.21M	Perf Week	2.92%
Market Cap	98.77M	Forward P/E	-	EPS next Y	-0.19	Insider Trans	0.00%	Shs Float	34.04M	Perf Month	6.47%
Income	4.47M	PEG	-	EPS next Q	-0.04	Inst Own	17.77%	Short Float	0.88%	Perf Quarter	-0.40%
Sales	0.00M	P/S	-	EPS this Y	-125.93%	Inst Trans	23.85%	Short Ratio	2.40	Perf Half Y	9.78%
Book/sh	3.89	P/B	0.63	EPS next Y	-442.86%	ROA	2.26%	Short Interest	0.30M	Perf Year	8.33%
Cash/sh	3.56	P/C	0.69	EPS next 5Y	-	ROE	2.92%	52W Range	2.00 - 3.67	Perf YTD	6.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	2.85%	52W High	-32.70%	Beta	1.68
Dividend TTM	-	Quick Ratio	27.08	Sales past 5Y	-50.43%	Gross Margin	-	52W Low	23.50%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	27.08	EPS Y/Y TTM	127.62%	Oper. Margin	-	RSI (14)	55.18	Volatility	2.79% 4.12%
Employees	15	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	3.00	Target Price	3.25
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-501.88%	Payout	0.00%	Rel Volume	0.97	Prev Close	2.49
Sales Surprise	-	EPS Surprise	-5100.00%	Sales Q/Q	-	Earnings	Nov 08	Avg Volume	124.98K	Price	2.47
SMA20	3.19%	SMA50	4.11%	SMA200	0.84%	Trades		Volume	121,499	Change	-0.80%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-12-23	Downgrade	Canaccord Genuity	Buy → Hold	$30 → $3
Feb-18-22	Initiated	Cantor Fitzgerald	Overweight	$20
Apr-20-21	Initiated	Canaccord Genuity	Buy	$27
Feb-09-21	Initiated	National Securities	Buy
Dec-03-20	Initiated	Alliance Global Partners	Buy	$11
Mar-11-20	Initiated	Aegis Capital	Buy	$5.50
Sep-11-19	Initiated	Ladenburg Thalmann	Buy	$7
Dec-11-17	Resumed	B. Riley FBR, Inc.	Buy	$20
May-26-16	Reiterated	FBR Capital	Outperform	$15 → $20
Dec-01-15	Reiterated	H.C. Wainwright	Buy	$24 → $25
Nov-19-15	Initiated	FBR Capital	Outperform	$15
Apr-13-15	Resumed	MLV & Co	Buy	$27 → $30
Jan-30-14	Reiterated	Aegis Capital	Buy	$30 → $35
Jan-08-14	Reiterated	Aegis Capital	Buy	$25 → $30
Jan-08-14	Initiated	MLV & Co	Buy	$27
Dec-03-13	Initiated	Aegis Capital	Buy	$25

Show Previous Ratings

Oct-07-24 10:00AM	Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt (PR Newswire)
Aug-15-24 05:12AM	Oramed: Q2 Earnings Snapshot (Associated Press Finance)
Jul-08-24 03:07PM	3 Micro-Cap Moonshots for Fearless Investors (InvestorPlace)
Jun-26-24 09:05AM	Oramed Letter to Shareholders (PR Newswire) +14.73%
09:00AM	Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock (PR Newswire)
11:53PM	Loading…
May-09-24 11:53PM	ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
06:51PM	Oramed: Q1 Earnings Snapshot (Associated Press Finance)
Mar-19-24 09:00AM	Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation (GlobeNewswire)
Mar-07-24 10:53AM	ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
Feb-20-24 08:30AM	Oramed Letter to Shareholders (PR Newswire)
Nov-10-23 05:03AM	Oramed: Q3 Earnings Snapshot (Associated Press Finance)
Oct-24-23 08:30AM	PhaseV Raises $15 Million to Push the Boundaries of ML for Clinical Trial Optimization (PR Newswire)
Oct-05-23 10:13AM	ORMP: Distribution Deals, JVs in Anticipation of Commercializing ORMD-0801 (Zacks)
Sep-22-23 11:38AM	Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company (PR Newswire)
Sep-21-23 06:11PM	Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company (PR Newswire)
04:05PM	Loading…
04:05PM	Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc. (GlobeNewswire)
Sep-13-23 09:00AM	Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder (GlobeNewswire) -5.56%
Aug-02-23 07:45AM	Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally (PR Newswire)
Jun-20-23 07:55AM	Oramed to Present at the 83rd American Diabetes Association Conference (PR Newswire)
Jun-17-23 09:54AM	Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
May-30-23 11:06AM	ORMP: Advancing Development Efforts in China (Zacks Small Cap Research)
May-18-23 07:55AM	Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit (PR Newswire) +13.22%
May-15-23 09:05AM	Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China (PR Newswire) +10.60%
May-12-23 01:03PM	Oramed: Q1 Earnings Snapshot (AP Finance)
May-02-23 10:51AM	Conservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug Company (Bloomberg) +6.53%
May-01-23 04:45PM	Oramed Appoints Ben Shapiro to its Board of Directors (PR Newswire) +7.93%
Mar-27-23 06:57AM	The past year for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable (Simply Wall St.)
Feb-09-23 07:55AM	Oramed Pharmaceuticals Issues Shareholder Update (PR Newswire) +5.77%
Jan-25-23 08:05AM	ORMP: ORA-D-013-1 Failed To Meet Endpoints; Ending T2D Oral Insulin Efforts (Zacks Small Cap Research)
Jan-12-23 12:30PM	Oramed Pharmaceuticals Stock Plummets After Insulin Test Results (The Wall Street Journal) -76.46%
11:50AM	Loading…
11:50AM	Why Oramed Pharmaceuticals Stock Is Crashing Today (Motley Fool)
08:02AM	Orameds oral insulin pill fails; stock is down 72% (MarketWatch)
06:19AM	Oramed Pharma Shares Sink After Diabetes Candidate Fails In Phase 3 Study (Benzinga)
Jan-11-23 08:00PM	Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes (PR Newswire) +5.78%
Jan-08-23 07:38AM	Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation (Simply Wall St.)
Jan-04-23 07:55AM	Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes (PR Newswire)
Dec-21-22 08:25AM	Oramed Letter to Shareholders (PR Newswire) +14.25%
Dec-05-22 08:30AM	Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022 (ACCESSWIRE)
Nov-29-22 08:40AM	Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism (PR Newswire)
Nov-21-22 10:45AM	ORMP: Data from NASH Phase 2 Study Positive Takeaways (Zacks Small Cap Research)
Nov-17-22 01:12PM	Oramed Pharma Shares Fall After Additional Data From Oral Insulin Study (Benzinga)
12:25PM	Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH (PR Newswire)
Nov-16-22 05:06AM	Oramed Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.) -8.56%
Nov-14-22 07:55AM	Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea (PR Newswire)
Nov-10-22 04:30PM	Oramed Reports Third Quarter 2022 Financial Results (PR Newswire) +5.96% +14.74%
Nov-09-22 08:40AM	Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH (PR Newswire) -6.19%
Oct-17-22 08:07AM	Oramed Pharmaceuticals (NASDAQ:ORMP) shareholders have earned a 27% CAGR over the last three years (Simply Wall St.) +7.69%
Oct-07-22 11:06AM	Oramed Pharmaceuticals' Oral COVID-19 Vaccine Candidate Shows Safety, Immunogenicity In Early Study (Benzinga) -7.19%
08:40AM	Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine (PR Newswire)
Sep-13-22 11:59AM	Oramed Oral Insulin Shows Evidence For NASH Treatment (Benzinga)
08:40AM	Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate (PR Newswire)
Sep-06-22 07:55AM	Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire) -12.36%
Aug-25-22 09:15AM	ORMP: Upcoming data from ORA-D-013-1 & NASH studies could be catalysts (Zacks Small Cap Research)
Aug-01-22 07:40AM	We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth (Simply Wall St.)
Jul-26-22 07:55AM	Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial (PR Newswire)
Jul-12-22 02:22PM	Why Oramed Pharmaceuticals Stock Is On Fire Today (Motley Fool)
Jul-11-22 07:55AM	Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference (PR Newswire) +5.61%
Jul-08-22 05:56PM	Why Oramed Pharmaceuticals Stock Rocketed Higher Today (Motley Fool) +44.37%
Jul-07-22 07:55AM	Oramed Letter to Shareholders (PR Newswire) +12.70%
Jun-01-22 07:55AM	Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board (PR Newswire) -5.40%
May-24-22 08:10AM	Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes (PR Newswire) -5.23%
May-18-22 07:55AM	Oramed to Present at H.C. Wainwright Global Investment Conference (PR Newswire) -13.42%
May-10-22 07:12AM	Shareholders in Oramed Pharmaceuticals (NASDAQ:ORMP) have lost 58%, as stock drops 22% this past week (Simply Wall St.) -6.12%
May-03-22 08:10AM	Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1 (PR Newswire)
Apr-27-22 08:10AM	ORMP: Broadening IP Protection, Positive Physician Indicators & Studies Advancing (Zacks Small Cap Research)
Apr-05-22 08:25AM	Oramed Granted NASH Patent in Europe (PR Newswire)
Apr-04-22 08:25AM	Oramed Appoints Yadin Rozov to its Board of Directors (PR Newswire)
Mar-29-22 08:25AM	Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians (PR Newswire)
Mar-22-22 08:25AM	Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes (PR Newswire)
Mar-16-22 08:25AM	Oramed Completes Patient Enrollment in Phase 2 Oral Insulin NASH Trial (PR Newswire) +6.88%
Mar-10-22 08:25AM	Oramed to Present at Barclays Global Healthcare Conference (PR Newswire)
Feb-23-22 11:25AM	ORMP: Moving Multiple Candidates & Studies Forward (Zacks Small Cap Research) -6.11%
Feb-22-22 05:38AM	We're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Rate (Simply Wall St.)
Jan-12-22 08:45AM	Oramed Issues Annual Message to Shareholders (PR Newswire)
Jan-05-22 07:30AM	Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins (PR Newswire) -8.29%
Dec-29-21 06:14AM	Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh (MarketWatch)
06:00AM	Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia (PR Newswire)
06:00AM	Israel's Oramed gets Vietnam pre-order for 10 mln COVID-19 vaccine doses (Reuters)
Dec-14-21 08:00AM	Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa (PR Newswire) -6.76%
Dec-08-21 07:30AM	Oramed Pharmaceuticals Appoints Chief Legal Officer (PR Newswire)
Nov-24-21 08:40AM	Oramed to Join MSCI USA Small Cap Index (PR Newswire)
Nov-23-21 08:25AM	Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study (PR Newswire)
Nov-18-21 07:40AM	Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America (PR Newswire)
Nov-11-21 09:25AM	Oramed to Present at H.C. Wainwright 7th Annual Israel Conference (PR Newswire)
Nov-10-21 10:19AM	ORMP: Financing Enhances Flexibility to Advance Multiple Opportunities (Zacks Small Cap Research) -6.30%
Nov-08-21 08:10AM	Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules (PR Newswire) +10.88%
Nov-03-21 11:59AM	Oramed Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules (PR Newswire) -12.89%
Oct-29-21 07:25AM	Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial (PR Newswire)
Sep-23-21 08:25AM	Oramed to Present at Cantor Fitzgerald Virtual Global Healthcare Conference (PR Newswire) +8.94%
Sep-15-21 08:10AM	Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment (PR Newswire)
Sep-09-21 08:25AM	Oramed to Present at H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-26-21 07:05AM	ORMP: Multiple Opportunities Advance; Senior Team Expands to Support Growth (Zacks Small Cap Research)
Aug-24-21 08:25AM	Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials (PR Newswire)
06:26AM	Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Will Probably Have Their Compensation Approved By Shareholders (Simply Wall St.)
Aug-16-21 08:25AM	Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism (PR Newswire) -13.97%
Aug-09-21 08:40AM	Oramed to Present at Canaccord Genuity's 41st Annual Growth Conference (PR Newswire) +15.50%
Aug-05-21 06:40AM	Oravax to Present Keynote Talk on Oral COVID-19 Vaccine at the Arena International Vaccines Virtual Conference 2021 (PR Newswire) +14.70%
Jul-29-21 08:25AM	Oramed Pharmaceuticals Appoints Chief Commercial Officer (PR Newswire) +5.58%
Jul-21-21 11:44AM	Oramed Will Soon Start Clinical Trials For Oral COVID-19 Vaccine In Israel, Out licensed Injectable Version To Premas Biotech In India (Benzinga) +9.66%
08:25AM	Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial (PR Newswire)

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ORMP

Oramed Pharmaceuticals, Inc

Upgrade your FINVIZ experience